BioSpace News Archive

Company expanding pipeline of novel treatments for cardiovascular disease

Glenmark Pharmaceuticals, a global pharmaceutical company, today announced the initiation of a Phase 2b clinical trial of GBR 830, a novel, investigational treatment for moderate-to-severe atopic dermatitis.

- Scientists demonstrate the potential of improving therapy with patient-derived tumor infiltrating lymphocytes (TILs) by applying RXi’s novel sd-rxRNA compounds specific to PD-1. Targeting the PD-1/PD-L1 axis can enhance the ex vivo expansion rate and in vivo longevity and functionality of these T-cells and thereby have the potential to improve Adoptive Cell Therapy (ACT) outcomes in cancer patients.

Product is the generic version of Endo International plc’s original Vasostrict® formulation

International Multi-center Study Compares Effectiveness of the Hydrus® Microstent to Two iStent® Trabecular Micro-Bypass Stents in Standalone Glaucoma

Financing designed to fund the Company through Pre-Market Approval of the Tack Endovascular System for the treatment of post-angioplasty dissections above the knee.

If approved by the FDA, esketamine nasal spray would be the first medication for treatment of patients with major depressive disorder at imminent risk for suicide.

Surgical reconstruction company looks to forge long-term relationship with strategic investment group.

PMD-026 is the first RSK inhibitor to demonstrate potential disease-modifying properties in triple-negative breast cancer

Expect to Open Expansion Cohorts in Phase 1 Trial in Mid-2018, Including Cohorts Evaluating SY-1365 as a Single and Combination Agent in Multiple Ovarian Cancer Patient Populations